Nemera designs and manufactures a full range of drug delivery systems including asthma inhalers, insulin pens, auto-injectors and nasal pumps. The Nemera Group originally comprised two businesses at acquisition in May 2014: a healthcare devices business (Nemera) as well as a prescription retail containers and closures business (Centor, which was sold in 2015), both carved-out of Rexam plc. In October 2018, we reinvested in Nemera alongside another investor to support the next phase of Nemera’s growth. Following Nemera’s achievements since 2014, the current strategy focuses on organic and acquisitive growth so that Nemera reaches its potential as a leader in its different markets and geographies. To add to its existing product research and development capabilities, in August 2019 Nemera acquired US medical device developer Insight Product Development. Nemera subsequently rebranded and relaunched the Company’s combined development arm as the “Insight Innovation Center”, which has enabled the business to pursue opportunities from multiple pre-production design phases. Between 2014 and 2018, we supported Nemera in:

Investors 1